NBIX vs WST
Neurocrine Biosciences vs West Pharmaceutical Services — AI-powered side-by-side comparison
NBIX
Neurocrine Biosciences
63
Buy
VS
WST
West Pharmaceutical Services
71
Buy
| Metric | NBIX | WST |
|---|
| AI Score |
63
|
71
|
| Price |
$163.26
|
$353.62
|
| P/E Ratio |
23.18×
|
44.99×
|
| ROE |
14.7%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
98.0%
|
36.8%
|
| Debt / Equity |
0.11×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.2%
|
| RSI (14) |
37.5
|
61.3
|
| Beta |
0.386
|
1.159
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for NBIX versus WST.
WST leads by 8 points.
WST scores 71/100 (Buy) versus NBIX at 63/100 (Buy).
NBIX Committee View
50% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- ROE of 21.1% shows genuine earnings power backing the valuation — Value
- Revenue growing 34.4% YoY -- genuine top-line momentum — Growth
- EPS growing 101.3% YoY — Growth
Bear Case
- Price-to-book of 4.3x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
- Bollinger bandwidth of 16.0% signals elevated volatility — Risk
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 4 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical